

# Chao-Hung Kuo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8065671/publications.pdf>

Version: 2024-02-01

52  
papers

1,783  
citations

430874

18  
h-index

276875

41  
g-index

53  
all docs

53  
docs citations

53  
times ranked

2017  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tailored susceptibility-guided therapy via gastric juice PCR for the first-line <i>H. pylori</i> eradication, a randomized controlled trial. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1450-1457.	1.7	10
2	IL-33 regulates M1/M2 chemokine expression via mitochondrial redox-related mitophagy in human monocytes. <i>Chemico-Biological Interactions</i> , 2022, 359, 109915.	4.0	15
3	Immunological map in COVID-19. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 547-556.	3.1	9
4	Tetracyclineâ€levofloxacin versus amoxicillinâ€levofloxacin quadruple therapies in the secondâ€line treatment of <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2021, 26, e12840.	3.5	11
5	Significant association between blood lead (Pb) level and haemoglobin A1c in non-diabetic population. <i>Diabetes and Metabolism</i> , 2021, 47, 101233.	2.9	7
6	Diabetes care during the outbreak of 2019 novel coronavirus disease (COVID-19) in Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 658-659.	1.9	0
7	Trend of changes in antibiotic resistance in <i>Helicobacter pylori</i> from 2013 to 2019: a multicentre report from Taiwan. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482097699.	3.2	19
8	Emergency department infection control strategies in response to COVID-19. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 568-569.	1.9	1
9	Equivalent efficacies of reverse hybrid and concomitant therapies in firstâ€line treatment of <i>Helicobacter pylori</i> infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1731-1737.	2.8	17
10	Infection control strategies of patient diversion in response to COVID-19. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 765-767.	1.9	0
11	Predictive modeling of blood pressure during hemodialysis: a comparison of linear model, random forest, support vector regression, XGBoost, LASSO regression and ensemble method. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 195, 105536.	4.7	69
12	Allergic rhinitis is a risk factor of gastro-esophageal reflux disease regardless of the presence of asthma. <i>Scientific Reports</i> , 2019, 9, 15535.	3.3	9
13	Clinical efficacy of 60-mg dexamprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 1347-1356.	4.3	5
14	Current applications of fecal microbiota transplantation in intestinal disorders. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 327-331.	1.9	6
15	Risks of substance uses, alcohol flush response, <i>Helicobacter pylori</i> infection and upper digestive tract diseasesâ€An endoscopy crossâ€sectional study. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 341-349.	1.9	3
16	Postendoscopic retrograde cholangiopancreatography pancreatitis. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 195-201.	1.9	8
17	Gastric juiceâ€based PCR assay: An alternative testing method to aid in the management of previously treated <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2019, 24, e12568.	3.5	9
18	Fecal microbiota transplantation: Review and update. <i>Journal of the Formosan Medical Association</i> , 2019, 118, S23-S31.	1.7	263

#	ARTICLE	IF	CITATIONS
19	Stromal C-type lectin receptor COLEC12 integrates H. pylori, PGE2-EP2/4 axis and innate immunity in gastric diseases. <i>Scientific Reports</i> , 2018, 8, 3821.	3.3	28
20	Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of <i>Helicobacter pylori</i> Infection in a Randomized Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1427-1433.	4.4	32
21	<i>Helicobacter pylori</i> Infection-Induced Hepatoma-Derived Growth Factor Regulates the Differentiation of Human Mesenchymal Stem Cells to Myofibroblast-Like Cells. <i>Cancers</i> , 2018, 10, 479.	3.7	18
22	An Aptamer-Based Capacitive Sensing Platform for Specific Detection of Lung Carcinoma Cells in the Microfluidic Chip. <i>Biosensors</i> , 2018, 8, 98.	4.7	30
23	Silver decorated copper oxide (Ag@CuO) nanocomposite enhances ROS-mediated bacterial architecture collapse. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 155, 399-407.	5.0	49
24	Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3298-3316.	2.3	19
25	Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for <i>Helicobacter pylori</i> . <i>Journal of Digestive Diseases</i> , 2017, 18, 537-542.	1.5	16
26	Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of <i>Helicobacter pylori</i> . <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-6.	1.5	6
27	First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease. <i>World Journal of Gastroenterology</i> , 2017, 23, 8395-8404.	3.3	6
28	A Rapid and Accurate Method to Evaluate <i>Helicobacter pylori</i> Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric Juice. <i>Medicine (United States)</i> , 2016, 95, e3458.	1.0	13
29	Suppression of IL-8 signaling axis by 17 $\beta$ -estradiol inhibits human mesenchymal stem cells-mediated gastric cancer invasion. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 962-972.	3.6	17
30	Diagnosis of <i>Helicobacter pylori</i> infection: Current options and developments. <i>World Journal of Gastroenterology</i> , 2015, 21, 11221.	3.3	292
31	Comparison of Second-Line Quadruple Therapies with or without Bismuth for <i>Helicobacter pylori</i> Infection. <i>BioMed Research International</i> , 2015, 2015, 1-6.	1.9	18
32	Eight Weeks of Esomeprazole Therapy Reduces Symptom Relapse, Compared With 4 Weeks, in Patients With Los Angeles Grade A or B Erosive Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 859-866.e1.	4.4	23
33	Genetic polymorphisms of CYP2C19 and IL1B have no influence on esomeprazole treatment for mild erosive esophagitis. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 255-259.	1.9	2
34	17 $\beta$ -Estradiol Inhibits Mesenchymal Stem Cells-Induced Human AGS Gastric Cancer Cell Mobility via Suppression of CCL5- Src/Cas/Paxillin Signaling Pathway. <i>International Journal of Medical Sciences</i> , 2014, 11, 7-16.	2.5	12
35	The Utilization of a New Immunochromatographic Test in Detection of <i>Helicobacter pylori</i> Antibody from Maternal and Umbilical Cord Serum. <i>BioMed Research International</i> , 2014, 2014, 1-6.	1.9	7
36	Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin Achieves a High Eradication Rate for <i>Helicobacter pylori</i> Infection after Failure of Sequential Therapy. <i>Helicobacter</i> , 2014, 19, 74-79.	3.5	39

#	ARTICLE	IF	CITATIONS
37	Eradication of <i>Helicobacter pylori</i> infection. Kaohsiung Journal of Medical Sciences, 2014, 30, 167-172.	1.9	18
38	17 $\beta$ -Estradiol inhibition of IL-6 $\alpha$ Src and Cas and paxillin pathway suppresses human mesenchymal stem cells $\alpha$ mediated gastric cancer cell motility. Translational Research, 2014, 164, 232-243.	5.0	16
39	Apigenin has anti-atrophic gastritis and anti-gastric cancer progression effects in <i>Helicobacter pylori</i> -infected Mongolian gerbils. Journal of Ethnopharmacology, 2014, 151, 1031-1039.	4.1	42
40	Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line <i>Helicobacter pylori</i> therapy: a randomized controlled trial. Journal of Antimicrobial Chemotherapy, 2013, 68, 222-228.	3.0	50
41	Current Pharmacological Management of Gastroesophageal Reflux Disease. Gastroenterology Research and Practice, 2013, 2013, 1-12.	1.5	27
42	The Optimal First-Line Therapy of <i>Helicobacter pylori</i> Infection in Year 2012. Gastroenterology Research and Practice, 2012, 2012, 1-8.	1.5	34
43	Lansoprazole $\alpha$ based sequential and concomitant therapy for the first $\alpha$ line <i>Helicobacter pylori</i> eradication. Journal of Digestive Diseases, 2012, 13, 232-238.	1.5	64
44	<i>Helicobacter pylori</i> Infection. Medicine (United States), 2011, 90, 180-185.	1.0	41
45	Rabeprazole Can Overcome the Impact of CYP2C19 Polymorphism on Quadruple Therapy. Helicobacter, 2010, 15, 265-272.	3.5	40
46	Sequential and Concomitant Therapy With Four Drugs Is Equally Effective for Eradication of H pylori Infection. Clinical Gastroenterology and Hepatology, 2010, 8, 36-41.e1.	4.4	225
47	Dual specimens increase the diagnostic accuracy and reduce the reaction duration of rapid urease test. World Journal of Gastroenterology, 2010, 16, 2926.	3.3	16
48	Efficacy of levofloxacin-based rescue therapy for <i>Helicobacter pylori</i> infection after standard triple therapy: a randomized controlled trial. Journal of Antimicrobial Chemotherapy, 2009, 63, 1017-1024.	3.0	86
49	Polymorphism in COX-2 modifies the inverse association between <i>Helicobacter pylori</i> seropositivity and esophageal squamous cell carcinoma risk in Taiwan: a case control study. BMC Gastroenterology, 2009, 9, 37.	2.0	16
50	Short-term Celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model. World Journal of Gastroenterology, 2009, 15, 4907.	3.3	10
51	A Better Method for Preventing Infection of Percutaneous Endoscopic Gastrostomy. Journal of Gastrointestinal Surgery, 2008, 12, 358-363.	1.7	10
52	Evaluating the Validity of the Serologic Test for Detecting <i>Helicobacter pylori</i> Infection in Mongolian Gerbils. Kaohsiung Journal of Medical Sciences, 2007, 23, 545-551.	1.9	0